Its not just as an investor. I am so frustrated as an ex-patient. Look at this article. The editors/publishers salivating over sheep studies in tenocytes and the potential:
https://www.genengnews.com/news/stem-cell-therapy-repairs-injured-tendons/
Meanwhile we are on a company that has been treating humans for ten years. Ten years! Aaaaaah!!
We do live in the digital information world, we live in the digital MISinformation world. How is OCC not in journals worldwide with this innovation that is decades ahead of others in the area?
J&J Partnership, page-352
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.010(2.35%) |
Mkt cap ! $86.97M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 41.5¢ | $36.29K | 86.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11096 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 26292 | 2 |
View Market Depth
| Last trade - 15.55pm 01/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |